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Abstract
Ultralow molecular weight (ULMW) heparins are sulfated glycans that are clinically used to treat
thrombotic disorders. ULMW heparins range from 1500 to 3000 daltons, corresponding from 5 to
10 saccharide units. The commercial drug Arixtra (fondaparinux sodium) is a structurally
homogeneous ULMW heparin pentasaccharide that is synthesized through a lengthy chemical
process. Here, we report 10- and 12-step chemoenzymatic syntheses of two structurally
homogeneous ULMW heparins (MW = 1778.5 and 1816.5) in 45 and 37% overall yield,
respectively, starting from a simple disaccharide. These ULMW heparins display excellent in vitro
anticoagulant activity and comparable pharmacokinetic properties to Arixtra, as demonstrated in a
rabbit model. The chemoenzymatic approach is scalable and shows promise for a more efficient
route to synthesize this important class of medicinal agent.
Heparin has been used as an anticoagulant drug for more than 50 years (1). It is currently
marketed in three forms: un-fractionated (UF) heparin [average molecular weight (MWavg)
~14000]; low molecular weight (LMW) heparin (MWavg ~6000); and the synthetic ultralow
molecular weight (ULMW) heparin pentasaccharide Arixtra (GlaxoSmithKline) (MW
1508.3). UF heparin is used in surgery and kidney dialysis due to its relatively short half-life
and its safety for renal-impaired patients (2). LMW heparins and Arixtra, introduced over a
decade ago, have played an increasingly important role in preventing venous thrombosis
among high-risk patients (3, 4) because of their more predictable anticoagulant doses, long
half-lives, and reduced risks of osteoporosis (5). Recent research on LMW heparin has
resulted in the European approval of Bemiparin (6), a second-generation LMW heparin, and
the U.S. approval of a generic LMW heparin, M-Enoxaparin.
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UF heparin is isolated from porcine intestine or bovine lung, and LMW heparins are
prepared through the chemical or enzymatic degradation of this animal-sourced UF heparin.
Worldwide distribution of contaminated heparin in 2007 has raised concerns over the
reliability and safety of animal-sourced heparins and LMW heparins (7, 8). As a result, a
cost-effective method for preparing new synthetic heparins is highly desirable (9). Heparin
is a polysaccharide that consists of a disaccharide-repeating unit of either iduronic acid
(IdoA) or glucuronic acid (GlcA) and glucosamine (GlcN) residues, each capable of
carrying sulfo groups. The locations of the sulfo groups and IdoA residues are crucial for
heparin’s anticoagulant activity. The chemical synthesis of Arixtra, the most successful
example to date for preparing a synthetic heparin (10), entails ~50 steps with an overall
yield of ~0.1% (11); as such, Arixtra is the most expensive drug among heparins (12).
Efforts to improve the synthesis of Arixtra with a purely chemical approach have achieved
only limited success (13).
A chemoenzymatic approach, relying on a series of heparan sulfate (HS) biosynthetic
enzymes, mimics the biosynthesis of heparin and HS (fig. S1) (14). Heparin and HS have
similar disaccharide repeating units; however, heparin carries more sulfo groups and a
higher level of IdoA residues and possesses the strongest anticoagulant activity among this
class of polysaccharide isolated from natural sources (15). HS polymerases synthesize the
backbone with a disaccharide repeating unit of GlcA and N-acetylated glucosamine
(GlcNAc). Subsequent modification relies on sulfotransferases and an epimerase, including
N-deacetylase/N-sulfotransferase [containing separate N-deacetylase and N-sulfotransferase
(NST) domains], C5-epimerase (C5-epi), 2-O-sulfotransferase (2-OST), 6-O-sulfotransferase
(6-OST), and 3-O-sulfotransferase (3-OST). Using these enzymes, we and others have
succeeded in the preparation of heparin polysaccharides (16–19) as well as structurally well-
defined HS oligosaccharides (20, 21). In particular, we developed a protocol to control the
size of the oligosaccharides, positions of the N-sulfo glucosamine, 2-O-sulfo IdoA or 6-
O-,N-disulfo glucosamine residues (20). However, the utility of this approach for the
targeted synthesis of medicinally significant heparin oligo-saccharides requiring all four
controlled sulfation steps, N-sulfation, 6-O-, 2-O- and 3-O-sulfation, has not been
demonstrated. Furthermore, until now, low recovery yields in each purification step have
cast doubt on the scalability of such chemoenzymatic synthesis.
We targeted two ULMW heparins, constructs 1 and 2, because of their apparent
compatibility with our chemoenzymatic approach (Fig. 1). These new constructs contain the
antithrombin (AT)–binding domains of porcine and bovine heparin, respectively, which
constitute the pharmacophores of anticoagulant heparin (22). Construct 1 also resembles the
AT-binding site of human heparin (23). Construct 2 has the same structure as Arixtra except
for replacement of a methyl aglycone with disaccharide 3. This structural similarity
facilitates comparison of the synthetic efficiency and the in vitro and in vivo biological
activities of these two homogeneous ULMW heparins to Arixtra.
Our synthesis of ULMW heparins includes backbone elongation and saccharide
modification (Fig. 1). Disaccharide 3 was chosen as the starting material because it can be
elongated by glycosyl transferases and can be prepared in multigram quantities from
heparosan, readily obtained by fermentation (24). Elongation of disaccharide 3 to
tetrasaccharide 4 was completed using two bacterial glycosyl transferases, N-acetyl
glucosaminyl transferase of Escherichia coli K5 (KfiA) (25) and heparosan synthase-2
(pmHS2) from Pasteurella multocida (26). Tetrasaccharide 4 was designed with an unnatural
monosaccharide, GlcNTFA (N-trifluoroacetyl glucosamine), because the N-TFA group can
be readily converted to an N-sulfo group (20) in a later step. In preparation of ULMW
heparin construct 1, tetrasaccharide 4 was elongated to heptasaccharide 5 in three steps, with
an overall yield of 80% (Fig. 1, steps a, b, and c). Heptasaccharide 5 was converted to the
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final product by a series of chemoenzymatic reactions, including conversion of the
GlcNTFA residue to GlcNS (Fig. 1, left column, steps d and e), epimerization and 2-O-
sulfation (Fig. 1, left column, step f; here, epimerization of GlcA to IdoA is accompanied by
2-O-sulfation using 2-OST to form an IdoA2S at residue D), 6-O-sulfation (Fig. 1, left
column, step g), and 3-O-sulfation (Fig. 1, left column, step h; the 3-O-sulfation occurred at
residue C). After these 10 steps, we obtained 3.5 mg of construct 1, corresponding to 45%
overall yield as assessed by nuclear magnetic resonance (NMR) spectral integration (fig.
S7). Selective epimerization/2-O-sulfation of residue D but not residue B (step f) takes
advantage of known enzyme specificity, as residue D is flanked by two GlcNS residues (27).
Similarly, in the 3-O-sulfation step (step h), 3-OST-1 selectively adds a 3-O-sulfo group to
residue C but not to residue E, because residue C is flanked by a GlcA residue at its
nonreducing end (28). In the conversion of heptasaccharide 5 to ULMW heparin construct 1,
it was critical to ensure that each modification was completed. For this purpose, small-scale
reactions were carried out in parallel using [35S]3′-phosphoadenosine 5′-phosphosulfate
([35S]PAPS) to form the 35S-labeled intermediates; monitoring by diethylami-noethyl high-
performance liquid chromatography (DEAE-HPLC) enabled optimization of the reagent
concentrations and reaction times required in the synthesis (fig. S2).
Two extra steps were required to add a GlcNS6S residue to the nonreducing end in the
synthesis of ULMW heparin construct 2. Tetra-saccharide 4 was first converted to
hexasaccharide 6, and the N-TFA groups were replaced by N-sulfo groups to afford
hexasaccharide 7 (Fig. 1, right column). Hexasaccharide 7 was elongated to a
heptasaccharide with a nonreducing end GlcNTFA (residue A). This heptasaccharide was
treated with C5-epi and 2-OST enzymes (Fig. 1, right column, step f) to place an IdoA2S at
residue D forming heptasaccharide 8. The introduction of a GlcNTFA residue at the
nonreducing end was a critical control point because it prevented the action of C5-epi and 2-
OST on the GlcA (residue B in step f). Heptasaccharide 8 was then converted to construct 2
in a sequential one-pot reaction format (Fig. 1, right column, steps d, e, g, and h). Carrying
out a small-scale reaction using [35S]PAPS ensured complete 6-O-sulfation (fig. S3). We
obtained 7.2 mg of ULMW heparin construct 2 in 12 steps with an overall yield of 37%, as
determined by NMR spectral integration (fig. S7). The synthesis of construct 2 was achieved
by rearranging the order of the modification and elongation steps without employing
additional enzymes or reagents, thus demonstrating that both structural control and target
diversification are possible in chemoenzymatic synthesis.
The structure of construct 1 was confirmed by electrospray ionization mass spectrometry
(ESI-MS), as well as one-dimensional (1D) and two-dimensional (2D) NMR analysis (Fig.
2). The 3-O-[35S]sulfo labeled construct 1 showed a single symmetric peak in a high-
resolution DEAE-HPLC trace (Fig. 2A), demonstrating that the purity of the product was
above 95% [in the large-scale reaction, purity was confirmed by poly-acrylamide gel
electrophoresis (PAGE)] (fig. S4). The ESI-MS analysis revealed construct 1 to have a
molecular mass of 1778.5 ± 0.8 daltons, which is identical to the expected calculated
molecular mass (1778.5 daltons) (Fig. 2B). High-resolution ESI-MS exhibited a signal at a
mass/charge ratio of 887.5313, consistent with [M-2H]2− (calculated mass/charge ratio,
887.5324). The 2D 1H NMR spectrum clearly demonstrates the presence of six anomeric
protons that resonate as doublets (Fig. 2, C and D). The small coupling constants (~3 Hz) of
three anomeric protons indicate α linkages between the A–B, C–D, and E–F rings; larger
coupling constants (~8 Hz) indicate β linkages between the B–C, D–E and F–G rings. The
presence of an internal IdoA2S is clearly indicated by a broad characteristic anomeric signal
at δ5.09 parts per million (ppm) that resonates ~0.6 ppm downfield relative to the anomeric
proton of GlcA residues. The complete assignment of the spectrum is shown in table S1A.
The structure of ULMW heparin construct 2 was confirmed using the same methods (fig. S6
and table S1B). High-resolution ESI-MS of construct 2 afforded a value consistent with
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[M-2H]2− of 906.5047 (calculated mass/charge ratio, 906.5056). A 1H-13C heteronuclear
multiple-quantum coherence (HMQC) analysis of constructs 1 and 2 further confirmed the
assignments discussed above (fig. S5). The structures of all intermediates were confirmed by
ESI-MS analysis (table S2).
The in vitro anticoagulant activities of construct 1 and 2 and in vivo pharmacokinetic
properties were next assessed and compared with those of Arixtra. We anticipated that these
ULMW heparins would exhibit anticoagulant activity by forming a 1:1 complex with AT,
which subsequently inactivates factor Xa in the blood coagulation cascade (29). The binding
affinities of AT to constructs 1 and 2 were 5.2 ± 0.2 nM and 9.1 ± 0.2 nM, respectively, very
similar to the 5.9 ± 1.5 nM value measured for Arixtra. Next, the in vitro anti-Xa activity of
each ULMW heparin was determined (16) (Fig. 3A). The median inhibitory concentration
(IC50) values of constructs 1 and 2 were 2.8 nM and 3.6 nM, respectively, again very close
to the 3.0 nM value measured for Arixtra. Finally, the pharmacokinetic (anti-Xa) property of
each ULMW heparin was examined in vivo using a rabbit model (30, 31). A standard curve
for each ULMW heparin was prepared in rabbit plasma (fig. S8). After the subcutaneous
administration of 120 μg per kg of weight of each ULMW heparin to three anesthetized
rabbits, plasma samples were collected and anti-Xa activity was measured over a 24-hour
period. The pharmacokinetic profiles of Arixtra, construct 1, and construct 2 were very
similar (Fig. 3B).
Construct 1 was resynthesized at a 15-fold greater scale to demonstrate the scalability and
reproducibility of this chemoenzymatic process (table S4). In this larger-scale synthesis, the
sequential one-pot format (steps d, e, g, f, and h in Fig. 1) was divided into three steps (fig.
S9), permitting the isolation and weighing of the intermediates and their complete structural
analysis using NMR and high-resolution MS (fig. S10 and table S4). Construct 1 (49 mg)
was obtained at >95% purity based on PAGE and NMR analysis, and in an overall yield of
38% (fig. S10).
Heparin oligosaccharides are generally perceived to be difficult to synthesize by chemical
methods. Long synthetic routes—necessitated by the introduction and removal of protecting
groups—lead to low overall yield, and there is a lack of efficient methods to separate side
products from desired intermediates. The chemo-enzymatic approach demonstrated here
shows that targeted, scalable, and high-efficiency synthesis of heparin oligosaccharides is
possible. We achieved this goal by carefully selecting the substrate size and optimizing the
sequence of sulfo group installation. Careful design of target structures offers a major
advance over our previous study (20) by avoiding by-product formation. For example, the
order for installing different types of sulfo groups is critically important in synthesizing
construct 1. The optimized sequence is N-sulfation followed by epimerization/2-O-sulfation,
6-O-sulfation, and 3-O-sulfation. Reversal of the order in which epimerization/2-O-sulfation
and 6-O-sulfation (or 6-O-sulfation and 3-O-sulfation) take place results in very low yields
of products. Target size selection is also critical, as heptasaccharides and larger
oligosaccharides are highly susceptible to sulfotransferase modification and undergo nearly
quantitative conversion to the desired intermediate without side products in each
modification step. Another crucial innovation was the improvement of purification
protocols, raising the 30 to 40% yields from each purification step described in our previous
study (20) to ~90% herein by coupling column purification with ESI-MS analysis.
Dabigatran, a direct thrombin inhibitor, was recently approved by the U.S. Food and Drug
Administration, a culmination of intensified efforts for new anticoagulant drug development
(32). However, none of the currently marketed anticoagulant drugs can replace heparin
because of its unique pharmacological properties. A cost-effective approach to prepare
heparin is important not only to secure the safety of the heparin supply chain but also to
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provide the opportunity to design derivatives that eliminate side effects. Although our
chemoenzymatic approach, with appropriate optimization, provides a general method for
preparing different heparins, including ULMW heparin, and in principle LMW heparin and
UF heparin, target selection is restricted by the substrate specificities of the enzymes.
Smaller targets, such as the Arixtra pentasaccharide, are more difficult to prepare because
pmHS2 inefficiently elongates glucosamine monosaccharide. Despite this drawback, our
chemo-enzymatic approach facilitates the scalable synthesis of larger targets through a
shorter route. Further optimization will certainly be necessary to make this method amenable
to industrial-scale synthesis. We recently developed a method to reduce the cost of the
synthesis of the sulfo donor, PAPS, by a factor of more than 5000 (33), facilitating large-
scale enzyme-based synthesis. The inclusion of a cofactor recycling system for the
regeneration of PAPS (34) could further reduce cost and eliminate potential PAP-involved
sulfotransferase inhibition. Continuing efforts should provide a generic and cost-effective
approach for the large-scale preparation of antithrombotic therapeutic agents with improved
safety and pharmacological effects.
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Chemoenzymatic synthetic schemes of ULMW heparin construct 1 and 2. The synthesis
started from disaccharide 3, and it was then elongated to tetrasaccharide 4. Eight additional
steps transformed 4 to construct 1 (left column). Steps d through h were combined in
sequential one-pot reaction format. Ten additional steps transformed 4 to construct 2 (right
column). The recovery yield at each purification step was determined by parallel synthesis
of the corresponding radioactively labeled oligosaccharide. KfiA, N-acetyl glucosaminyl
transferase of E. coli K5 strain; pmHS2, heparosan synthase-2 of Pasteurella multocida;
NST, N-sulfotransferase; PAPS, 3′-phosphoadenosine 5′-phosphosulfate; C5-epi, C5-
epimerase; 2-OST, 2-O-sulfotransferase; 6-OST, 6-O-sulfotransferase; 3-OST-1, 3-O-
sulfotransferase isoform 1. More synthesis details are given in table S3.
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Structural characterization of ULMW heparin construct 1. (A) The DEAE-HPLC profile of
a 35S-labeled product. (B) The ESI-MS spectrum of construct 1. Peaks 1 to 3 represent the
desulfated signals of quadruply charged ions. Peaks 4 to 7 represent the desulfated signals of
triply charged ions. Peaks 8 to 12 represent the desulfated signals of doubly charged ions.
(C) The 1D 1H NMR spectrum of construct 1. Peaks assigned to the anomeric protons of
each hexose ring (A to F) are labeled. (D) The 2D correlation spectroscopy spectrum of
construct 1 and the corresponding peak assignments of the anomeric protons that resonate as
doublets at δ5.48 (d, J = 3.23 Hz, 2H), 5.35 (d, J = 2.94 Hz, 1H), 5.09 (broad doublet, 1H),
4.53 (d, J = 8.11 Hz, 1H), and 4.46 (d, J = 8.07 Hz, 1H) ppm. The small coupling constants
(~3 Hz) of the anomeric protons indicate an α linkage, and the large coupling constants (~8
Hz) indicate a β linkage.
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Determination of the anticoagulant activities and pharmacokinetic properties of ULMW
heparin construct 1 and 2. (A) shows the anti-Xa activity using a chromogenic substrate.
Arixtra and constructs 1 and 2 were incubated with AT (240 nM), factor Xa (5.9 nM), and
the peptide substrate (289 μM). The activity of Xa was determined by the rate of increase of
the absorbance at 405 nm. The activity without drugs was defined as 100%. Each data point
represents the average of four determinations ± SD. (B) The pharmacokinetic profiles in
rabbits. Arixtra and constructs 1 and 2 were each independently administered
subcutaneously at 120 μg/kg to three rabbits (n = 3) and plasma samples were collected
from 0 to 24 hours. The anti-Xa activity of plasma samples was measured against a standard
curve (fig. S8). The area under the curve for Arixtra, construct 1, and construct 2 were 457,
473, and 802, respectively. Error bars, mean ± SD.
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